• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

AstraZeneca’s obesity drug shows promise as analysts see upside beyond consensus

by June 9, 2026
written by June 9, 2026

AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental weight-loss pill delivered encouraging mid-stage trial results, prompting investors and analysts to reassess whether the British drugmaker can challenge the dominance of Novo Nordisk and Eli Lilly.

The company said on Monday that patients receiving the highest dose of its once-daily obesity pill, elecoglipron, lost 11.8% of their body weight after 36 weeks of treatment.

After 26 weeks, patients had already achieved an average weight reduction of 10.5%, with weight loss continuing throughout the study period.

The results, presented at the American Diabetes Association meeting in New Orleans, provide the most detailed look yet at a drug AstraZeneca hopes could become a major growth driver in one of the pharmaceutical industry’s fastest-growing markets.

Trial results compare favourably with rivals

AstraZeneca first disclosed in February that the study had met its primary endpoints and would advance into late-stage testing, though it had not released detailed efficacy data at the time.

The latest results suggest elecoglipron could be competitive with oral obesity treatments being developed by industry leaders.

Novo Nordisk’s oral version of Wegovy has demonstrated around 14% weight loss in clinical studies, while Eli Lilly’s experimental pill Foundayo produced approximately 12% weight loss in a late-stage trial.

Although AstraZeneca’s candidate trails the strongest weight-loss data generated by injectable treatments, analysts say the results were stronger than many investors had anticipated.

Sharon Barr, AstraZeneca’s executive vice president for biopharmaceuticals research and development, said the findings demonstrated a competitive profile for elecoglipron and reinforced its potential to become a “blockbuster asset”.

She added that the company views the drug as a backbone for future combination therapies aimed at addressing obesity and related metabolic diseases.

Ambitious late-stage program planned

Buoyed by the encouraging data, AstraZeneca plans to launch an extensive phase 3 development program during the second half of the year.

The company intends to evaluate elecoglipron both as a standalone treatment and in combination with its diabetes medicine Farxiga.

Studies will include patients living with obesity as well as overweight individuals, regardless of whether they have type 2 diabetes.

Beyond weight loss, AstraZeneca also plans to investigate the drug’s potential role in treating heart failure and chronic kidney disease, reflecting growing interest across the pharmaceutical industry in the broader cardiometabolic benefits of obesity medicines.

Obesity drug success is a positive surprise

Analysts at Jefferies said the trial results exceeded expectations and strengthened AstraZeneca’s ability to compete in an increasingly crowded field.

The brokerage noted that the company is pursuing one of the most comprehensive obesity development programs among large pharmaceutical companies and could benefit from opportunities that are not yet fully reflected in market expectations.

“AstraZeneca is the only company for which obesity offers room for positive surprises, given that it isn’t factored into consensus expectations,” Jefferies said.

The obesity treatment market has become one of the most closely watched areas in healthcare, with demand for weight-loss drugs continuing to surge globally.

According to the World Health Organization, more than one billion people worldwide are living with obesity, creating a vast potential market for pharmaceutical companies.

Ruben Dalfovo, investment strategist at Saxo, said the market has become too large to be dominated by only two companies.

“The obesity market is now too large for only two companies,” Dalfovo said.

He noted that AstraZeneca’s strategy differs from those of Novo Nordisk and Eli Lilly, focusing not only on weight-loss efficacy but also on combination therapies, cardiometabolic expertise, pricing flexibility, and its strong presence in emerging markets.

While AstraZeneca’s weight-loss data remain below the most impressive results achieved by injectable treatments, analysts believe the company’s broader healthcare portfolio could provide a meaningful competitive advantage.

For investors, the latest trial results suggest AstraZeneca may be developing into one of the more credible challengers to the current obesity market leaders.

With a large phase 3 program set to begin later this year, attention will now turn to whether elecoglipron can replicate its mid-stage success and secure a place in what is expected to become one of the pharmaceutical industry’s largest therapy categories.

The post AstraZeneca’s obesity drug shows promise as analysts see upside beyond consensus appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Dow gains 270 points as chip stocks rally, oil prices retreat
next post
Micron stock falls on Tuesday: Why analysts still see gains ahead

related articles

Large-scale employee buyouts are not new, but big...

November 7, 2026

iMerit’s Radha Basu on how AI is reshaping...

November 7, 2026

SpaceX stock has dived after the midterms: Top...

November 7, 2026

Anthropic IPO faces test after recent selloff: What...

November 7, 2026

Star analyst says recent tech rout a ‘golden...

November 7, 2026

Anthropic IPO news: Valuation slips to $1.5 trillion...

November 7, 2026

Evening digest: Gold slips, Anthropic IPO faces valuation...

November 6, 2026

Nasdaq rebounds 1% as chip stocks recover; Dow...

November 6, 2026

Airbnb stock analysis after boosting its revenue and...

November 6, 2026

Micron stock rebounds 5% after huge selloff even...

November 6, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Senate hopeful says Texas home to the ‘best drag queens in the nation’ in resurfaced comments

    July 6, 2026
  • Dow sinks 480 points as AI selloff deepens, chip stocks extend losses

    July 17, 2026
  • Why Nvidia stock is down over 2% on Thursday

    September 10, 2026
  • Fact-checking Trump’s interview with NBC News’ ‘Meet the Press’

    June 8, 2026
  • Top reasons why South Korea’s KOSPI Index is falling today (Sept. 14)

    September 14, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026
  • 3

    CoreWeave stock jumps 10% as analysts see major backlog upside

    June 16, 2026
  • 4

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 5

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,372)
  • Stock (90)

Latest Posts

  • Soaring Astera Labs stock faces a major valuation risk: what next?

    June 9, 2026
  • Dow rises as S&P 500 nears record, SK Hynix debut boosts AI chip stocks

    July 10, 2026
  • Oil nears $110, yields near 5%: can KOSPI and Nikkei avoid a deeper rout?

    September 11, 2026

Recent Posts

  • Lloyds share price is at risk of a reversal despite UK GDP growth

    September 11, 2026
  • New Jersey sues Amazon, alleging poor pay and conditions for drivers

    August 4, 2026
  • Broadcom stock dubbed a ‘top pick’ ahead of Q3 earnings: find out more

    August 31, 2026

Editor’s Pick

  • Greggs’ shares jump 6% on improved sales and outlook

    September 30, 2026
  • Here’s why Micron stock looks unusually cheap before its next earnings

    September 16, 2026
  • Nikkei falls 1% as SoftBank sinks 6%: is Japan’s AI trade starting to crack?

    October 9, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock